Search
Lapatinib in combination with capecitabine is indicated for patients with HER2 who have previously received advanced or metastatic breast cancer including anthracycline, paclitaxel, and trastuzumab.
Lapatinib is a tyrosine kinase inhibitor that potently inhibits human epidermal growth factor receptor-1 (ErbB1) and human epidermal growth factor receptor-2 (ErbB2) tyrosine kinase activity. It is unique in that it can work through multiple pathways so that breast cancer cells cannot receive the signals needed to grow.
| Items | Technical index |
| Product name | Lapatinib |
| CAS NO. | 231277-92-2 |
| Molecular formula | C29H26ClFN4O4S |
| Molecular weight | 581.06 |
| Appearance | Yellow crystalline powder |
| Purity | 98%min |
| Product parameters | |
| Cas number: | 231277-92-2 |
| Appearance: | Yellow crystalline powder |
| Purity: | 98%min |
| Package details: | 1kg/foil bag; 25kg/drum |
| Brand: | Fortunachem |

Fortunachem Provides Not Only Professional Chemical Products But Also Professional Help
Keeping you up-to-date with all the latest information, news, and events about Fortunachem!
Quick Links
Add:
E-mail:
English
Español
français
العربية